24/7 Wall Street
03 Aug 2026, 15:44 UTC · 1h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Abbott Laboratories raised its full-year adjusted EPS guidance to a range of $5.45 to $5.60. — Direct upward revision of profitability guidance is a strong positive signal for share price appreciation.
+0.60Abbott's CEO expects accelerating sales and earnings growth in the second half of 2026. — Forward-looking positive guidance from leadership typically boosts investor sentiment and risk appetite for the stock.
+0.40Abbott achieved its fifth consecutive adjusted EPS beat with a Q2 result of $1.31 versus $1.28 consensus. — Consistent outperformance of analyst expectations suggests a strong underlying operational trend despite GAAP volatility.
+0.30Continue reading
6 related stories
Top 3 movers · tap to explore
Abbott's GAAP earnings were severely impacted by the $21 billion Exact Sciences acquisition, resulting in a 47.5% reported quarterly earnings decline. — Significant GAAP losses and amortization from M&A create financial optics that can deter conservative investors.
Abbott experienced segment weakness in Nutrition (-3.1%), U.S. Structural Heart (-9.8%), and rapid/molecular diagnostics (-7.3%). — Broad-based declines across core business segments indicate fundamental headwinds that could limit upside.
-0.20Which stocks this story touches
Despite GAAP losses from an acquisition, the company raised guidance and had its fifth straight adjusted EPS beat.
Shares collapsed over 50% year-to-date following two consecutive guidance cuts.
Shares are down over 14% year-to-date.
Stock is down nearly 10% year-to-date with split analyst coverage.
Mentioned as a successful historical stock pick by an analyst.
Mentioned only as a competitor to Abbott's CGM business.
[a_to_b] Abbott completed a $21 billion acquisition of Exact Sciences on March 23, 2026.
[mutual] Abbott competes against Dexcom in the continuous glucose monitor (CGM) market.
[mutual] The article identifies Boston Scientific as part of a stable peer set for Abbott.
[mutual] The article identifies Danaher as part of a stable peer set for Abbott.
[mutual] The article identifies Medtronic as part of a stable peer set for Abbott.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
24/7 Wall Street
1h ago
